Rockville, Maryland — September 23, 2026 — The global esophageal stents market is valued at USD 94.0 million in 2026 and is projected to reach USD 202.9 million by 2036, expanding at an 8.0% CAGR during the 2026–2036 forecast period, according to Fact.MR. The market reached USD 87.0 million in 2025. Demand is supported primarily by the need to relieve malignant esophageal obstruction and swallowing difficulty. The U.S. National Cancer Institute identifies self-expandable metal stenting as a method for palliating swallowing difficulty in patients with esophageal cancer.

Specialist teams also require covered devices for selected esophageal fistulas. The European Society of Gastrointestinal Endoscopy supports the use of covered metal stents for malignant tracheoesophageal or bronchoesophageal fistulas. In addition, difficult benign strictures are creating a selective opportunity for temporary or biodegradable stents; Japan's National Cancer Center reported regulatory approval of the ELLA-BD stent for refractory benign esophageal strictures in 2025.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=7699

Global Segment Leaders

Product — Self-expandable Metallic Stents: 69.2% share in 2026. Their established use in malignant dysphagia and availability in fully covered, partially covered, and uncovered configurations support their leading position.
Material — Metal: 45.3% share in 2026. Metallic structures provide the expansion characteristics and luminal support required to maintain esophageal patency.
End User — Hospitals: 55.2% share in 2026. Stent placement can require coordinated endoscopy, oncology, anesthesia, imaging, and complication-management services, supporting hospital demand.
Application — Esophageal Cancer Treatment: 74.2% share in 2026. The segment is driven by the need to relieve malignant obstruction and associated swallowing difficulty within cancer-care pathways.
Country-Level Performance

Country

CAGR

Key Growth Driver

Japan

7.1%

Japan's National Cancer Center announced in June 2025 that the ELLA-BD stent received approval on March 7, 2025 for refractory benign esophageal strictures.

Germany

6.3%

The Robert Koch Institute reports that only about one-third of esophageal tumors are diagnosed at an early stage, supporting continued demand for advanced-disease assessment and symptom management.

USA

5.6%

The National Cancer Institute identifies stenting within the palliation pathway for esophageal cancer patients experiencing swallowing obstruction.

France

5.5%

The French National Cancer Institute describes an esophageal prosthesis as a metal or plastic tube used to keep the esophagus open and permit feeding.

Italy

4.7%

The Italian Association of Medical Oncology includes stenting among approaches for substantial dysphagia and continues to document the burden of esophageal disease.

Regional Context

Japan records the highest CAGR among the five countries profiled by Fact.MR at 7.1%. The country's specialist endoscopy infrastructure and the 2025 approval of the biodegradable ELLA-BD stent create an additional treatment pathway for carefully selected patients with refractory benign esophageal strictures.

Germany follows at 6.3%, supported by established gastroenterology and oncology services and a continuing need for symptom management in patients diagnosed with advanced disease. The USA and France record CAGRs of 5.6% and 5.5%, respectively, with demand tied to malignant obstruction, palliative care, and restoration of oral intake. Italy, at 4.7%, is supported by cancer and gastroenterology services that use stenting selectively alongside nutritional and supportive interventions.

The full report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East & Africa, with country-level analysis for the USA, Japan, Germany, France, and Italy.

Competitive Landscape

Key companies profiled by Fact.MR include Boston Scientific Corporation, Cook Group Incorporated, C.R. Bard (BD), Merit Medical Systems Inc., M.I.Tech, Andratec GmbH, Ella CS, s.r.o., Endo-Flex GmbH, and BVM Medical Limited. The report identifies Boston Scientific, Cook, Merit Medical, M.I.Tech, ELLA-CS, and Endo-Flex as current esophageal-stent providers, while BVM Medical participates through distribution. C.R. Bard is identified as a legacy corporate identity following BD's 2017 acquisition of Bard, and Andratec participates in adjacent interventional-device categories.

Product portfolios include Boston Scientific's WallFlex esophageal stents, Cook's Evolution controlled-release system, Merit Medical's EndoMAXX and ALIMAXX-ES products, M.I.Tech's HANAROSTENT configurations, ELLA-CS's biodegradable technology, and Endo-Flex's self-expandable esophageal stents.

A notable recent development occurred in March 2025, when the ELLA-BD biodegradable stent received approval in Japan for refractory benign esophageal strictures. The National Cancer Center Japan announced the approval in June 2025 and noted that reimbursement procedures were the next step.

Explore More Related Studies Published by Fact.MR Research

Omics Lab Services Market

Antimicrobial PPE Market

Color Correcting Glasses Market

Intraoral X-Ray Market

About Fact.MR

Fact.MR is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, medical devices, and life sciences.

For more information on the full report, visit: Esophageal Stents Market